Home / Insurance / Does Medicare Cover Semaglutide? Insurance Guide 2...
MC
Reviewed by Marcus Chen Updated February 20, 2026

Does Medicare Cover Semaglutide? Insurance Guide 2026

Navigating Medicare coverage for semaglutide can feel overwhelming, but understanding the rules ensures you get the treatment you need. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide is FDA-approved for type 2 diabetes (Ozempic®) and chronic weight management (Wegovy®). Medicare’s coverage depends on the indication, plan type, and prior authorization requirements. This guide breaks down everything you need to know about accessing semaglutide through Medicare in 2026.

Does Medicare Cover Semaglutide for Diabetes?

Medicare does cover semaglutide when prescribed for type 2 diabetes under Part D (prescription drug plans) or Medicare Advantage (Part C) plans with drug coverage. Semaglutide, marketed as Ozempic, is included in most formularies because it’s a first-line therapy for glycemic control in adults with type 2 diabetes, supported by robust clinical evidence. The American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) recommend GLP-1 receptor agonists like semaglutide for patients with inadequate control on metformin or those with cardiovascular disease.

However, coverage isn’t automatic. Medicare requires prior authorization to confirm medical necessity, typically demonstrated by:

  • HbA1c levels ≥7.0% despite lifestyle modifications and metformin.
  • History of cardiovascular disease (semaglutide reduces major adverse cardiovascular events by 26%, per the SUSTAIN-6 trial).
  • Contraindications or intolerance to other diabetes medications (e.g., sulfonylureas, SGLT2 inhibitors).

If your plan denies coverage, you can appeal by submitting a Letter of Medical Necessity from your provider, citing clinical guidelines and trial data.

Does Medicare Cover Semaglutide for Weight Loss?

Medicare does not cover semaglutide for weight loss alone, even when prescribed as Wegovy. Under the Medicare Part D statute (Section 1860D-2(e)(2)(A)), weight loss drugs are explicitly excluded from coverage, regardless of obesity-related comorbidities. This exclusion stems from the Medicare Modernization Act of 2003, which prohibits Part D plans from covering drugs for anorexia, weight loss, or weight gain.

However, there are two exceptions:

  1. Off-label use for diabetes: If a provider prescribes Wegovy for a patient with type 2 diabetes and obesity (BMI ≥27 kg/m²), Medicare may cover it under the diabetes indication (though prior authorization is still required).
  2. Medicare Advantage plans: Some Part C plans offer supplemental benefits for obesity management, including semaglutide, but this is rare and varies by insurer.

For weight loss, patients must pay out-of-pocket (approximately $1,300–$1,600/month) or seek alternatives like liraglutide (Saxenda), which is also excluded but may be cheaper. Advocacy groups like the Obesity Action Coalition are pushing for legislative changes to expand Medicare coverage for anti-obesity medications.

How Much Does Semaglutide Cost With Medicare?

The cost of semaglutide with Medicare depends on your plan’s formulary tier, deductible, and copay/coinsurance structure. Here’s a breakdown for 2026:

1. Part D Plans (Standalone Prescription Drug Plans)

  • Tier placement: Semaglutide (Ozempic) is typically placed on Tier 3 (preferred brand) or Tier 4 (non-preferred brand).
    • Tier 3 copay: $45–$100/month (after deductible).
    • Tier 4 coinsurance: 33–50% of the drug’s list price (e.g., $400–$600/month for a $1,200 drug).
  • Deductible: Some plans require you to pay $505 (2026 standard deductible) before coverage kicks in.
  • Catastrophic coverage: After spending $8,000 out-of-pocket, you’ll pay 5% coinsurance or a small copay.

2. Medicare Advantage (Part C) Plans

  • Costs vary widely. Some plans offer $0 copays for Tier 3 drugs, while others charge 20–33% coinsurance.
  • Example: A plan might cover Ozempic at $30/month if you use a preferred pharmacy.

3. Manufacturer Savings Programs

  • Novo Nordisk offers a $25 copay card for Ozempic (diabetes) and Wegovy (weight loss), but Medicare beneficiaries are ineligible due to federal anti-kickback laws.
  • Patient assistance programs: NovoCare® may provide free semaglutide to low-income patients (income ≤400% of the federal poverty level).

4. Cost-Saving Tips

  • Switch to a lower-cost GLP-1: If semaglutide is too expensive, ask your provider about dulaglutide (Trulicity) or exenatide (Bydureon), which may be on a lower tier.
  • Use mail-order pharmacies: Many Part D plans offer 90-day supplies at a discount.
  • Apply for Extra Help: If you qualify for Low-Income Subsidy (LIS), your copay could drop to $4–$11/month.

Semaglutide Prior Authorization for Medicare

Medicare requires prior authorization (PA) for semaglutide to prevent overuse and ensure cost-effective prescribing. The process varies by plan but generally follows these steps:

1. Criteria for Approval

Your provider must document:

  • For diabetes (Ozempic):
    • HbA1c ≥7.0% despite ≥3 months of metformin (or intolerance).
    • Cardiovascular disease (prior MI, stroke, or PAD) or high risk (e.g., hypertension, dyslipidemia).
    • Failure or contraindication to other diabetes drugs (e.g., SGLT2 inhibitors, DPP-4 inhibitors).
  • For obesity (Wegovy, off-label):
    • BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities (e.g., hypertension, sleep apnea).
    • Documented failure of lifestyle interventions (diet/exercise) for ≥6 months.

2. Submission Process

  • Your provider submits a PA request to your Part D plan via:
    • Electronic prior authorization (ePA) through platforms like CoverMyMeds.
    • Fax or phone (slower, but some plans require it).
  • The plan reviews the request within 72 hours (standard) or 24 hours (expedited, if urgent).
  • Denial reasons include:
    • Incomplete documentation (e.g., missing HbA1c or BMI).
    • Lack of trial/failure with other diabetes drugs.
    • Weight loss indication (unless diabetes is also documented).

3. Appealing a Denial

If denied, you can:

  1. Request a redetermination (first-level appeal) within 60 days.
  2. Submit additional evidence, such as:
    • Clinical notes showing failed alternatives.
    • Peer-reviewed studies (e.g., SUSTAIN trials for semaglutide’s efficacy).
  3. Escalate to an independent review entity (IRE) if the redetermination fails.

How to Get Medicare to Cover Semaglutide

Getting Medicare to cover semaglutide requires strategic planning and provider collaboration. Here’s a step-by-step guide:

1. Confirm Your Plan’s Formulary

  • Log in to your Medicare account or call 1-800-MEDICARE to check if semaglutide is covered.
  • Use the Medicare Plan Finder tool to compare Part D plans in your area.

2. Work With Your Provider

  • Ask your doctor to:
    • Document medical necessity clearly (e.g., “Patient has HbA1c 8.2% on metformin 2g/day”).
    • Specify the diabetes indication (even if weight loss is a secondary goal).
    • Mention cardiovascular risk factors (e.g., “Patient has a history of MI; semaglutide reduces MACE by 26%”).
  • Request a trial of lower-cost alternatives first (e.g., metformin + sulfonylurea) to strengthen your case.

3. Submit a Strong Prior Authorization

  • Ensure your provider includes:
    • Lab results (HbA1c, lipid panel, eGFR).
    • Medication history (list of failed drugs).
    • BMI and comorbidities (if obesity is a factor).
  • Use clinical guidelines (ADA, AACE) to justify semaglutide.

4. Explore Appeals and Exceptions

  • If denied, appeal immediately with:
    • A Letter of Medical Necessity from your provider.
    • Supporting studies (e.g., SUSTAIN-6 for cardiovascular benefits).
  • Request a formulary exception if semaglutide is on a higher tier than alternatives.

5. Consider Alternative Coverage

  • Medicare Advantage plans: Some offer enhanced benefits for diabetes management.
  • State Pharmaceutical Assistance Programs (SPAPs): Some states (e.g., New York, Pennsylvania) help cover Part D costs.
  • Patient assistance programs: Novo Nordisk’s NovoCare® may provide free semaglutide if you meet income requirements.

What to Do If Medicare Denies Semaglutide

If Medicare denies coverage for semaglutide, don’t give up. You have multiple appeal options to overturn the decision:

1. Understand the Denial Reason

  • Common reasons include:
    • Lack of medical necessity (e.g., HbA1c <7.0%).
    • Weight loss indication (not covered under Part D).
    • Missing documentation (e.g., no proof of failed alternatives).
  • Request a detailed denial letter from your plan to identify gaps.

2. File a First-Level Appeal (Redetermination)

  • Deadline: 60 days from the denial date.
  • How to file:
    • Submit a written request to your Part D plan (include your Medicare number and denial notice).
    • Attach supporting documents, such as:
      • Provider letter explaining why semaglutide is necessary.
      • Clinical notes (e.g., “Patient has tried metformin, glipizide, and empagliflozin without success”).
      • Lab results (HbA1c, BMI, lipid panel).
      • Peer-reviewed studies (e.g., SUSTAIN trials).
  • Decision timeframe: 7 days (standard) or 72 hours (expedited).

3. Escalate to an Independent Review Entity (IRE)

  • If the redetermination is denied, request a second-level appeal to Maximus Federal Services (the IRE for Medicare).
  • Deadline: 60 days from the redetermination denial.
  • How to file:
    • Submit a written request to Maximus (address provided in your denial letter).
    • Include all prior appeal documents and any new evidence.
  • Decision timeframe: 7 days (standard) or 72 hours (expedited).

4. Request an Administrative Law Judge (ALJ) Hearing

  • If the IRE denies your appeal, you can request a hearing with an ALJ.
  • Deadline: 60 days from the IRE denial.
  • Threshold: Your case must involve ≥$180 in dispute (2026 amount).
  • How to file:
    • Submit Form CMS-20034A/B to the Office of Medicare Hearings and Appeals (OMHA).
    • Consider hiring a Medicare advocate or attorney for complex cases.
  • Decision timeframe: 90 days (average).

5. Explore External Options

  • State Health Insurance Assistance Program (SHIP): Free counseling to help with appeals.
  • Medicare Rights Center: Nonprofit offering appeal support.
  • Legal aid: Some organizations provide pro bono assistance for Medicare denials.

Medicare Alternatives If Semaglutide Is Not Covered

If Medicare denies semaglutide or the cost is prohibitive, consider these evidence-based alternatives:

1. Other GLP-1 Receptor Agonists

  • Dulaglutide (Trulicity):
    • Coverage: Typically on Tier 3 (lower copay than semaglutide in some plans).
    • Efficacy: Reduces HbA1c by ~1.0–1.5% (REWIND trial) and lowers cardiovascular risk.
    • Dosing: Weekly injection (may be more convenient than semaglutide’s titration).
  • **Liraglut